Bharat Parenterals Ltd - 541096 - Outcome Of Board Meeting
Outcome of the Board Meeting and Submission of Audited Financial Results (Standalone and Consolidated) for the Year ended 31st March, 2021.05-06-2021
05-06-2021
Bharat Parenterals Ltd - 541096 - Board Meeting Intimation for Intimation Of Meeting Of Board Of Directors For Approval Of Audited Financial Results For The Quarter And Year Ended 31St March,2021
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/06/2021 ,inter alia, to consider and approve With reference to the above, we would like to inform you that in terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the meeting of Board of Directors of the Company is scheduled to be held on 05th June, 2021, at the registered office of the Company situated at Survey No. 144 & 146, Jarod Samlaya road, Village Haripura., Ta. Savli, Vadodara-391520, to consider and approve: 1. The Audited financial results of the Company for the Quarter and Year ended on 31st March, 2021. Moreover, in terms of SEBI (Prohibition of Insider Trading) Regulations, 2015 vide our letter dated 31st March, 2021, the trading window shall remain closed from 01st April, 2021 till the completion of 48 hours after the declaration of Financial Results (both days inclusive). You are requested to take the same on record.27-05-2021
Bharat Parenterals Ltd - 541096 - Introducing - 'FAVIPIRAVIR ORAL SUSPENSION 100Mg/Ml" For Treatment Of COVID-19.
With reference to the captioned subject, we are glad to inform you that the company has received the license and authorization from Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO), New Delhi for the manufacturing and marketing of 'FAVIPIRAVIR ORAL SUSPENSION 100mg/ml' which will be used for treatment of COVID-19 disease. Further, the product patent has been already filed under fast track approval and the Company is the first one in the Indian Market receiving the license and authorization to manufacture and market 'FAVIPIRAVIR ORAL SUSPENSION 100mg/ml'.22-05-2021
Bharat Parenterals Ltd - 541096 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBharat Parenterals Ltd 2CINL24231GJ1992PLC018237 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: LUBHANSHI JHALANI Designation: COMPANY SECRETARY EmailId: lubhanshi.jhalani@bplindia.in Name of the Chief Financial Officer: JIGNESH SHAH Designation: CHIEF FINANCIAL OFFICER EmailId: jignesh.shah@bplindia.in Date: 23/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.23-04-2021
Bharat Parenterals Ltd - 541096 - Shareholding for the Period Ended March 31, 2021
Bharat Parenterals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here21-04-2021
Bharat Parenterals Ltd - 541096 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, For The Half Year Ended 31St March, 2021
We enclose herewith Certificate under Regulation 40(9) of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, for the half year ended 31st March, 2021 issued by CS Niraj Trivedi, Practicing Company Secretary, Vadodara. We request you to kindly take the same on record.15-04-2021
Bharat Parenterals Ltd - 541096 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, For The Half Year Ended 31St March, 2021
With reference to the captioned subject, we enclose herewith Certificate under Regulation 40(9) of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, for the half year ended 31st March, 2021 issued by CS Niraj Trivedt, Practicing Company Secretary, Vadodara. We request you to kindly take the same on record.15-04-2021
Bharat Parenterals Ltd - 541096 - Compliance Certificate For The Period Ended 31St March,2021
Compliance Certificate - Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201512-04-2021
Bharat Parenterals Ltd - 541096 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- LUBHANSHI JHALANIDesignation :- Company Secretary and Compliance Officer12-04-2021
Bharat Parenterals Ltd - 541096 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are forwarding herewith the Confirmation Certificate pursuant to provisions of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 duly sent and confirmed by Adroit Corporate Services Private Limited viz., Company's Registrar and Share Transfer Agent, registered with Securities and Exchange Board of India for the period ended on 31st March, 2021. We request you to kindly take the same on record. Yours faithfully, For Bharat Parenterals Limited Lubhanshi Jhalani Company Secretary & Compliance Officer12-04-2021